ASCO Live Update | Professor Niels van de Donk: Four Key Advantages of the Trispecific Antibody JNJ-5322 in R/R MM

ASCO Live Update | Professor Niels van de Donk: Four Key Advantages of the Trispecific Antibody JNJ-5322 in R/R MM

2025.06.24
At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Professor Niels van de Donk from VU University Medical Center, Amsterdam, presented the preliminary results of a first-in-human phase I study of a novel trispecific antibody (TsAb) for relapsed/refractory multiple myeloma (R/R MM) in an oral presentation (Abstract #S100). Oncology Frontier – Hematology Frontier invited Prof. van de Donk for an in-depth discussion on the study's findings and clinical implications. Highlights of the conversation are summarized below.
An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China

An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China

2025.05.27
An international event focusing on cellular therapy for blood diseases is approaching! From August 17 to September 1, 2025, in Tuanbo Campus, Tianjin, China, the International Workshop on Cell Therapy of Blood Diseases hosted by the Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Science (IHCAMS) and supported by the Ministry of Science and Technology of the People's Republic of China will be grandly held.
Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang

Advancing AML Treatment in Asia: Insights from Professor Jianxiang Wang

2025.05.19
We are thrilled to share an exclusive presentation by Professor Jianxiang Wang from the Institute of Hematology, Chinese Academy of Medical Sciences. In this engaging session, Professor Wang delves into the groundbreaking findings of the Phase 3 Commodore study, recently published in Leukemia. This study provides critical new evidence on the efficacy of gilteritinib, a FLT3-inhibiting TKI, in treating relapsed or refractory FLT3-mutated acute myeloid leukemia (AML) among predominantly Asian patients.
Global First, with China’s Participation! Drs. Wenyu Yang & Wenbin An Discuss the Development, Highlights, and Clinical Relevance of the First International Expert Consensus on Pediatric Chronic Phase CML

Global First, with China’s Participation! Drs. Wenyu Yang & Wenbin An Discuss the Development, Highlights, and Clinical Relevance of the First International Expert Consensus on Pediatric Chronic Phase CML

2025.04.25
The recently published “Management of children and adolescents with chronic myeloid leukemia in chronic phase: International pediatric chronic myeloid leukemia expert panel recommendations” in the prestigious journal Leukemia marks a historic milestone as the first international expert consensus focused on chronic-phase chronic myeloid leukemia (CML) in children and adolescents.
From Pioneering Efforts to Global Leadership – Academician Xiaojun Huang Charts China’s Transformative Journey

From Pioneering Efforts to Global Leadership – Academician Xiaojun Huang Charts China’s Transformative Journey

2025.04.23
From April 11 to 12, 2025, the Hematology Branch of the China International Exchange and Promotive Association for Medical and Health Care(CPAM) held its annual academic meeting in Qingdao, Shandong Province, alongside the “Hua Tuo Project” MDT Forum. During the event, Academician Xiaojun Huang—Conference Chair, Director of the Hematology Branch of the CPAM , and professor at Peking University People’s Hospital—delivered a landmark keynote titled "50 Years of Hematopoietic Stem Cell Transplantation." His talk provided a comprehensive review across four dimensions: historical development, China’s contributions, advances in immunotherapy, and future perspectives. He highlighted milestone achievements and global impacts—especially the original “Beijing Protocol”—and underscored how Chinese innovations are reshaping the international transplant landscape, offering valuable insights for hematologists worldwide.